Last reviewed · How we verify
Ovarian Stimulation with CC+rFSH
CC+rFSH is a combination hormonal therapy that stimulates ovarian follicle development by blocking negative feedback (clomiphene citrate) while directly stimulating follicle growth (recombinant FSH).
CC+rFSH is a combination ovarian stimulation protocol that uses clomiphene citrate (CC) to enhance endogenous FSH secretion and exogenous recombinant FSH (rFSH) to directly stimulate follicle development for assisted reproductive technology. Used for Ovarian stimulation for assisted reproductive technology (IVF, ICSI), Infertility treatment in women requiring controlled ovarian hyperstimulation.
At a glance
| Generic name | Ovarian Stimulation with CC+rFSH |
|---|---|
| Sponsor | Fundación Santiago Dexeus Font |
| Drug class | Gonadotropin combination therapy |
| Target | FSH receptor (FSHR); estrogen receptor (ER) antagonism |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Clomiphene citrate (CC) acts as a selective estrogen receptor modulator that blocks negative feedback on the hypothalamic-pituitary axis, increasing endogenous gonadotropin release. Recombinant follicle-stimulating hormone (rFSH) directly stimulates the FSH receptor on ovarian granulosa cells to promote follicle recruitment and development. Together, this combination enhances ovarian stimulation for assisted reproductive technology.
Approved indications
- Ovarian stimulation for assisted reproductive technology (ART) in women with infertility
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Abdominal bloating and discomfort
- Headache
- Mood changes
- Hot flushes
Key clinical trials
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders (PHASE3)
- Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ovarian Stimulation with CC+rFSH CI brief — competitive landscape report
- Ovarian Stimulation with CC+rFSH updates RSS · CI watch RSS
- Fundación Santiago Dexeus Font portfolio CI